Can weight loss injections suddenly cause vision loss?

The U.S. FDA has asked manufacturers of the diabetes and obesity drugs Ozempic, Wegovy, Mounjaro and Zepbound to add a warning to their prescribing labels linking the treatments to NAION, a rare condition that can cause permanent vision loss. The label change follows the agency's review of reported cases and signals that the side effect is now considered a recognized risk for the drug class. The move matters because these GLP-1 therapies are used by millions of patients worldwide and are central to the fast-growing obesity market. Dr. Uğur Yayla, an ophthalmology specialist at Medipol University Pendik Hospital, said the mechanism and which patients face the greatest risk are still being clarified. Investors and clinicians will watch whether European regulators such as the EMA follow the FDA, and whether label updates affect prescribing or sales trends.